MDxHealth Licenses Methylation Technology to Takara Bio Inc. for Scientific Research Market
30-Nov-2010
- USA
Under the agreement, Takara Bio Inc. (Takara) has licensed the use of MDxHealth's MSP technology, the most widely applied methylation technology, for the scientific research market in exchange for an upfront fee plus royalties from future sales utilizing this technology. Other terms were not disclosed.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.